Cancer Control. 2000;8(1) 

Introduction

  • CLB-9473, NCI-P97-0097 Phase I/II Study of Omega-3 Fatty Acids in Advanced Cancer Patients With Cachexia

    Chairperson: C. Patrick Burns. Telephone: 319-356-2038. Lead organization: Cancer and Leukemia Group B. Age range: 18 and over.

  • E-1Z95 Phase II Study of Flecainide for the Treatment of Chronic Neuropathic Pain

    Chairperson: Charles F. Von Gunten. Lead organization: Eastern Cooperative Oncology Group. Age range: over 18.

  • NU-98CC6, NCI-G00-1705 Phase II Study of Megestrol and Progressive Resistance Training in Patients With Cancer Related Weight Loss

    Chairman: Jamie Hayden Von Roenn. Telephone: 312-695-6180. Lead organization: Robert H. Lurie Comprehensive Cancer Center. Age range: over 18.

  • NU-97X1, NCI-G00-1685 Phase II Study of Octreotide as Palliative Therapy for Inoperable Bowel Obstruction Secondary to Cancer

    Chairperson: J. Cameron Muir. Telephone: 312-908-5250. Lead organization: Robert H. Lurie Comprehensive Cancer Center. Age range: over 18.

  • NU-98CC7, NCI-G00-1706 Phase II Study of Progressive Resistance Training (PRT) Plus Epoetin Alfa in Cancer Patients With Anemia Related Fatigue

    Chairperson: Jamie Hayden Von Roenn. Telephone: 312-695-6180. Lead organization: Robert

H. Lurie Comprehensive Cancer Center, Northwestern University. Age range: over 18.

  • NCCTG-979253, NCI-P98-0133 Phase III Randomized Study of Epoetin Alfa in Anemic Patients With Advanced Cancer Undergoing Chemotherapy

    Chairperson: Thomas E. Witzig. Telephone: 507-284-2176. Lead organization: North Central Cancer Treatment Group. Age range: 18 and over.

  • IBCSG-17-98, EU-98077 Phase III Randomized Study of Hormone Replacement Therapy in Menopausal or Perimenopausal Women With Prior Stage 0-II Breast Cancer

    Chairperson: C. Rageth. Telephone: 0041-1-733-21-76. Lead organization: International Breast Cancer Study Group. Age range: not specified.

  • NCCTG-989201, NCI-P00-0168 Phase III Randomized Study of Ondansetron in Patients With Advanced Cancer and Chronic Nausea and Emesis Not Due to Antineoplastic Therapy

    Chairperson: Steven Alberts. Telephone: 507-284-4918. Lead organization: North Central Cancer Treatment Group. Age range: not specified.

  • CCCWFU-97300, NCI-P00-0174, CCCWFU-0009 Phase III Randomized Study of the Effect of Megestrol on Weight and Quality of Life in Patients With Head and Neck Cancer

    Chairperson: Kathryn Mc-Connell Greven. Telephone: 336-716-4981. Lead organization: Comprehensive Cancer Center of Wake Forest University Baptist Medical Center. Age range: over 18.

  • CAN-NCIC-SC17 Phase III Randomized Study of Two Different Sustained Release Formulations of Morphine Followed by Dextromethorphan or Placebo Plus Morphine for Patients With Chronic Cancer Pain

    Chairperson: Eduardo Bruera. Telephone: 713-792-6085. Lead organization: NCIC-Clinical Trials Group. Age range: 16 and over.

  • E-3Z93, NCI-P95-0068 Randomized Pilot Study to Evaluate Educational Intervention and Behavioral Skills Training for Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer

    Chairperson: Charles Cleeland. Telephone: 713-745-3470. Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.

  • SJHCH-TM1, NCI-V00-1618 Randomized Study of Stress Reduction in Older Women With Stage II, III, or IV Breast Cancer

    Chairperson: Rhoda Pomerantz. Telephone: 773-665-3606. Lead organization: St. Joseph Health Centers & Hospital. Age range: 55 and over.

  • URCC-3996, NCI-P00-0160 Randomized Study of the Efficacy of Patient Information in Alleviating Nausea and Emesis in Cancer Patients Receiving Chemotherapy

    Chairperson: Gary R. Morrow. Telephone: 716-275-5513. Lead organization: University of Rochester Cancer Center. Age range: 18 and over.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....